Blashki T G, Mowbray R, Davies B
Br Med J. 1971 Jan 16;1(5741):133-8. doi: 10.1136/bmj.1.5741.133.
A controlled double-blind trial of amitriptyline at two dosage levels (75 and 150 mg/day), amylobarbitone (150 mg/day), and an inert substance for a period of four weeks was conducted on four matched groups of women attending their general practitioners and suffering from a depressive illness. Improvement at 7 and 28 days was noted on several measures of depression and anxiety in all treatment groups. Of these treatments amitriptyline 150 mg/day was the most consistent in relieving depression and anxiety. Troublesome side effects were equally distributed among the four treatments.
对四组匹配的、因患有抑郁症而就诊于全科医生的女性进行了一项对照双盲试验,试验为期四周,涉及两种剂量水平(75毫克/天和150毫克/天)的阿米替林、戊巴比妥(150毫克/天)以及一种惰性物质。在所有治疗组中,第7天和第28天时,多项抑郁和焦虑指标均显示有所改善。在这些治疗方法中,150毫克/天的阿米替林在缓解抑郁和焦虑方面最为稳定。令人烦恼的副作用在四种治疗方法中分布相同。